297 related articles for article (PubMed ID: 28189351)
1. [Ototoxicity in head and neck cancers after radiotherapy and chemoradiotherapy: From primary prevention to tertiary prevention].
Espenel S; Garcia MA; Guy JB; Vallard A; Ben Mrad M; Langrand-Escure J; El Meddeb Hamrouni A; Trone JC; Xia Y; Rancoule C; Magné N
Cancer Radiother; 2017 Feb; 21(1):77-83. PubMed ID: 28189351
[TBL] [Abstract][Full Text] [Related]
2. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
3. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.
Chan SH; Ng WT; Kam KL; Lee MC; Choi CW; Yau TK; Lee AW; Chow SK
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1335-42. PubMed ID: 18922648
[TBL] [Abstract][Full Text] [Related]
4. Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study.
Braun LH; Braun K; Frey B; Wolpert SM; Löwenheim H; Zips D; Welz S
Strahlenther Onkol; 2018 Dec; 194(12):1124-1131. PubMed ID: 30109361
[TBL] [Abstract][Full Text] [Related]
5. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature.
Theunissen EA; Bosma SC; Zuur CL; Spijker R; van der Baan S; Dreschler WA; de Boer JP; Balm AJ; Rasch CR
Head Neck; 2015 Feb; 37(2):281-92. PubMed ID: 24478269
[TBL] [Abstract][Full Text] [Related]
6. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
Scobioala S; Parfitt R; Matulat P; Kittel C; Ebrahimi F; Wolters H; Am Zehnhoff-Dinnesen A; Eich HT
Strahlenther Onkol; 2017 Nov; 193(11):910-920. PubMed ID: 28887665
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
[TBL] [Abstract][Full Text] [Related]
8. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Das N; Kaushal D; Patro SK; Pareek P; Dixit A; Soni K; Prakasan Nair N; Choudhury B; Goyal A
Acta Otolaryngol; 2021 Sep; 141(9):885-893. PubMed ID: 34486907
[TBL] [Abstract][Full Text] [Related]
9. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
Paulino AC; Lobo M; Teh BS; Okcu MF; South M; Butler EB; Su J; Chintagumpala M
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1445-50. PubMed ID: 20231075
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
12. Cochlea CT radiomics predicts chemoradiotherapy induced sensorineural hearing loss in head and neck cancer patients: A machine learning and multi-variable modelling study.
Abdollahi H; Mostafaei S; Cheraghi S; Shiri I; Rabi Mahdavi S; Kazemnejad A
Phys Med; 2018 Jan; 45():192-197. PubMed ID: 29329660
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of sensorineural hearing loss in nasopharyngeal carcinoma patients: comparison between treatment with radiotherapy alone and chemoradiotherapy.
Wei Y; Zhou T; Zhu J; Zhang Y; Sun M; Ding X; Wang D; Li H; Li B
Cell Biochem Biophys; 2014 Jul; 69(3):433-7. PubMed ID: 24510513
[TBL] [Abstract][Full Text] [Related]
14. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
[TBL] [Abstract][Full Text] [Related]
15. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy.
Cheraghi S; Nikoofar P; Fadavi P; Bakhshandeh M; Khoie S; Gharehbagh EJ; Farahani S; Mohebbi A; Vasheghani M; Zare M; Nikoofar A; Mahdavi SR
Med Oncol; 2015 Jul; 32(7):200. PubMed ID: 26071124
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
[TBL] [Abstract][Full Text] [Related]
17. [Intensity modulated radiotherapy for head and neck cancer, dose constraint for normal tissue: Cochlea vestibular apparatus and brainstem].
Guimas V; Thariat J; Graff-Cailleau P; Boisselier P; Pointreau Y; Pommier P; Montbarbon X; Laude C; Racadot S
Cancer Radiother; 2016 Oct; 20(6-7):475-83. PubMed ID: 27614519
[TBL] [Abstract][Full Text] [Related]
18. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
19. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
20. [Concurrent chemoradiotherapy for head neck cancers. Should organs at risk dose constraints be revisited ?].
Lapeyre M; Biau J; Miroir J; Moreau J; Gleyzolle B; Brun L; Racadot S; Graff-Cailleaud P
Cancer Radiother; 2020 Oct; 24(6-7):586-593. PubMed ID: 32861607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
